OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sullivan on the Examination of Tebentafusp in Uveal Melanoma

July 6th 2022

Ryan J. Sullivan, MD, discusses the examination of tebentafusp-tebn in uveal melanoma.

Dr. Rampal on the Potential Utilization of Navtemadlin in Relapsed/Refractory AML and MPNs

July 6th 2022

Raajit K. Rampal, MD, PhD, discusses the potential utilization of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.

Dr. Shah on the Importance of Genetic Testing in GI Cancer

July 6th 2022

Manish A Shah, MD, discusses the importance of genetic testing in gastrointestinal cancer.

Dr. Park on the Role of Cemiplimab in Advanced Basal Cell Carcinoma

July 1st 2022

Soo Park, MD, discusses the role of cemiplimab-rwlc (Libtayo) in advanced basal cell carcinoma.

Dr. Yoon on Updated Data on Tislelizumab Plus Chemotherapy in ESCC

June 30th 2022

Harry H. Yoon, MD, discusses updated findings from the phase 3 RATIONALE-306 trial in esophageal squamous cell carcinoma.

Dr. Vogel on the OS Benefit of Durvalumab/Tremelimumab in Unresectable HCC

June 30th 2022

Arndt Vogel, MD, discusses the outcomes of the phase 3 HIMALAYA trial in unresectable hepatocellular carcinoma.

Dr. Luke on the Importance of a Multidisciplinary Approach in Basal Cell Carcinoma

June 30th 2022

Jason Luke, MD, FACP, discusses the importance of a multidisciplinary approach in basal cell carcinoma.

Dr. Monk on the Need for Molecular Testing in Ovarian Cancer

June 30th 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the importance of molecular testing in ovarian cancer.

Dr. Schwartzberg on the Use of Myriad Genomic Testing in Cancer Care

June 30th 2022

Lee S. Schwartzberg, MD, FACP, discusses the utilization of genomics in cancer care.

Dr. Lipson on the Current Treatment Landscape of Basal Cell Carcinoma

June 30th 2022

Evan J. Lipson, MD, discusses the current treatment landscape in locally advanced, unresectable, or metastatic basal cell carcinoma.

Dr. Kim on the Future Role of Y-90 in Patients with Unresectable HCC

June 29th 2022

Edward Kim, MD, discusses the future role of Y-90 in patients with unresectable hepatocellular carcinoma.

Dr. Erogolu on the Rationale for Investigating Patterns in BRAF+ Metastatic Melanoma

June 28th 2022

Zeynep Eroglu, MD, discusses the rationale for investigating patterns of outcomes in patients with metastatic melanoma harboring BRAF mutations.

Dr. Botta on Unmet Needs in the Salvage Setting of GI Cancers

June 28th 2022

Gregory Botta, MD, PhD, discusses unmet needs in the salvage setting of gastrointestinal cancers.

Dr. Gupta on the Results of the PARADIGM Study in Urothelial Cancer

June 28th 2022

Shilpa Gupta, MD, discusses the results of the PARADIGM study in locally advanced or metastatic urothelial cancer.

Dr. Ghosh on the Safety Data Seen With Liso-cel in LBCL

June 27th 2022

Nilanjan Ghosh, MD, PhD, discusses the low toxicity levels with lisocabtagene maraleucel that were seen in patients with relapsed/refractory large B cell lymphoma in the phase 3 TRANSFORM trial.

Dr. Lunning on the FDA Approval of Liso-cel in LBCL

June 24th 2022

Matthew A. Lunning, DO, FACP, discusses how the FDA approval of lisocabtagene maraleucel expands treatment options for patients with large B-cell lymphoma.

Dr. Tan on the Potential of Elacestrant in the EMERALD Trial in ER+ Breast Cancer

June 24th 2022

Antoinette R. Tan, MD, MHSc, discusses the potential of the oral selective estrogen receptor degrader elacestrant being investigated in the phase 3 EMERALD trial in estrogen receptor–positive breast cancer.

Dr. Nakayama on the Current Treatment Landscape of Ovarian Cancer

June 24th 2022

John Nakayama, MD, discusses the current treatment landscape of ovarian cancer and where he hopes the field advances in the future.

Dr. Khorana on Rates of Young-Onset Pancreatobiliary Adenocarcinoma

June 24th 2022

Alok Khorana, MD, discusses increasing rates of young-onset pancreatobiliary adenocarcinoma.

Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic Cancer

June 24th 2022

Lacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer.